The last broker analysts value it at 60c (MC would be around $360M) on FDA approval for just pediatric......they are planning to do both pediatric and adult studies in parallel (this time it will be double blind and independent) so I think if the results are as good or better, it will be higher than last time pending FDA approval as they have made tech and protocol enhancements in preparation for the US clinical trials this time around.
********** downramps Resapp, page-296
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| RAP (ASX) Chart |
Day chart unavailable